Jim Davis

Jim is the executive vice president of Advera Health Analytics (previously AdverseEvents Inc). He brings over 12 years of experience in commercial strategy, global sales management and execution, business development, and product development. He has over 9 years of specific domain expertise in biopharma market research, intelligence, and data. Prior to joining Advera Health Analytics, Jim served as the Global Head of Sales for the BioPharm Solutions Suite at Infinata, Inc. (A part of The Mergermarket Group, a Financial Times Group company and a division of Pearson, Plc.)
July 16, 2015
As Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab) get closer to market, the safety question is one of the remaining pieces of the puzzle that unfortunately can't be solved immediately until real-world data starts to become available. However, as payers assess the risk-benefit of Repatha and Praluent vs the gold standard statins, there are questions that CAN be answered immediately.
May 12, 2015
If Amarin's lawsuit is successful, and FDA reverses its current stance, I believe that data and information will be exchanged more freely leading to an overall benefit to drug safety
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.